1-7 of 9     Next

Welcome to the first issue of the 2018: Everyday Urology- Oncology Insights. The start of the year has ushered in significant advancements and therapeutic approvals for GU oncology management. Along with these recent developments presented at the 2018 ASCO GU meeting, we anticipate additional and important presentations at upcoming major meetings. 

The cover story, An Unmet Need is Met: (The PROSPER Study): Evaluating the Safety and Efficacy Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer discusses 2 phase III nmCRPC trials and how they will significantly alter the evaluation and treatment for nmCRPC patients. At ASCO GU 2018, these two phase III presentations were highly anticipated and, assuredly, exceeded the expectations of most researchers and clinicians:
Welcome to Issue 4 of Everyday Urology - Oncology Insights.  This month, Evan Yu, M.D. and Sumanta (Monty) Kumar Pal, M.D. will review and analyze the impact of current clinical trials on patient care, as described by the cover article, The Importance of Clinical Trials for Genitourinary Malignancies. Drs. Yu and Pal will address numerous and important key clinical questions embracing four main genitourinary malignancies: prostate, bladder/urothelial, renal and testicular germ cell cancers, explaining that if not for the dedication of researchers, investigators, and patients (trial subjects) who collectively dedicate their energies to clinical trials, we would not have the evidence-based information which results in regulatory approval and subsequent US and global access for life-prolonging therapies for the genitourinary cancers we diagnose and manage.
Welcome to Issue 3 of Everyday Urology - Oncology Insights which focuses on the exceptionally rapid and groundbreaking advances in both advanced prostate and bladder cancer evaluation and management. 

Petros Grivas’ cover article, Updates on Immunotherapy for Urothelial Cancer, not only succinctly reviews the five new approved immuno-oncology therapies (IO), aka checkpoint (PD pathway) inhibitors and their milestone clinical trials, but also offers guidance regarding treatment selection strategy as well as IO selection within the context of chemotherapeutic options.  Additionally, he discusses a basis for monitoring efficacy of response, potential biomarkers and genomic markers predictive of patient benefit and also reviews the ongoing possibilities for combination strategies. Clearly, both advanced bladder and kidney cancer care information and subsequent
Optimizing the patient clinical outcome (prolonging survival, preserving quality of life, and preventing complications) while avoiding excessive healthcare economic burden is tantamount to the overall improvement of the healthcare system.  Certainly, combining an integrative, multidisciplinary approach, which can attain these aforementioned goals will align with the “Triple Aim”, which proposes that improving the U.S. health care system requires simultaneous pursuit of three aims: improving the experience of care, improving the health of populations, and reducing per capita costs of health care.  

Our first issue of 2017 emphasizes a well-known, yet an evolving and important, theme: optimizing the successful multidisciplinary collaboration amongst oncologic physicians; and furthermore, the importance of patient involvement, also known as, patient-physician shared decision making (and assuredly, successful integrated care).  This multidimensional approach to decision making and treatment has numerous advantages in all phases of the patient care experience, the physician expectation of successful genitourinary oncology outcomes, and efficiency for the healthcare ecosystem.  The authors of our three featured articles in this issue include the specialties of: urology, cardiology and nuclear medicine.

Over the past year, we’ve been honored to provide you with the inaugural issues of Everyday Urology-Oncology Insights. This fourth issue completes our publications for 2016—a year highlighted by important developments in the optimal management and treatment of patients with genitourinary cancers. Everyday Urology-Oncology Insights has strived in our inaugural year of publication to provide our readership with timely articles, written by internationally renowned GU oncology experts. I’d like to thank our editorial team and our advisory board for their dedication to selecting and reviewing the relevant content of interest for urologists, medical oncologists, radiation oncologists, and radiologists.
In this issue of Everyday Urology-Oncology Insights, we will share with you several articles which are based upon recent presentations from the CME course at the annual Large Urology Group Practice Association (LUGPA) meeting held this past November in Chicago, Illinois. I was honored to be the co-chairman along with my colleague, Dr. David Chaikin. This year’s LUGPA CME program was entitled: “Optimizing Bladder Disease Management”.

1-7 of 9     Next